NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts
NCT00649584 2014-12-18A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesSeagen Inc.Phase 1 Terminated44 enrolled
NCT00365274 2014-06-02SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell LymphomaNational Cancer Institute (NCI)Phase 2 Terminated6 enrolled 3 charts